Transplant Oncology : A Frontier in Multidisciplinary Cancer Care / edited by Maen A. Abdelrahim.

Format:

Book

Contributor:

Abdelrahim, Maen A., editor.

Language:

English

Subjects (All):

Liver--Cancer.

Liver.

Liver--Cancer--Chemotherapy.

Physical Description:

1 online resource (716 pages)

Edition:

First edition.

Place of Publication:

London, England : Academic Press, [2025]

Summary:

**Selected for 2025 Doody's Core Titles® in Transplantation Surgery**Transplant Oncology: A Frontier in Multidisciplinary Cancer Care summarizes new and evolving scientific findings and discoveries in the field of cancer and transplants and gives guidance on future directions and related research.

Contents:

Front Cover

TRANSPLANT ONCOLOGY

Copyright

Dedication

Contents

List of contributors

About the editor

Foreword

Preamble

Preface

Acknowledgments

Introduction

Transplant oncology

I - Transplant oncology: An evolving field in cancer care

1 - Transplant oncology: Concept, history, and evolution

Inherent learning orientation gives to transplant oncology a competitive advantage over other therapeutic strategies

Transplant oncology shares the same principles as surgical oncology

Transplant oncology aims at substantial transplant benefit while preserving competitive patient survival. Tumor response to ...

Hepatocellular carcinoma

Perihilar and intrahepatic cholangiocarcinoma (pCC and iCC)

The concept of oncologic acuity should be incorporated in organ allocation and patients' priority systems

Immunomanipulation and organ resuscitation offer opportunities to transplant oncology

Conclusion and evolutionary landscape

References

2 - Prehistory of transplant oncology era

Evolution of liver transplantation and early experience in hepatobiliary malignancies

Rise of transplant oncology: The "4E's"

Future perspectives

Abbreviations

II - Transplantations for oncological indications

3 - Hepatocellular carcinoma

Pathophysiology and staging of HCC

Diagnosis of HCC

Staging of HCC

Curative treatment

Surgical resection

Criteria for liver transplantation

Approaches to liver transplantation

Decreasing the drop out rate

Downstaging and bridging therapy

Immunosuppression after transplant

Recurrence after transplantation

Neoadjuvant therapies

Conclusion

4 - Cholangiocarcinoma and liver transplantation

Introduction.

Treatment options for localized cholangiocarcinoma: A comprehensive overview

Liver transplantation for peri-hilar cholangiocarcinoma

Neoadjuvant chemoradiation therapy and survival outcomes

Comparison with and without neoadjuvant therapy

Selection criteria and neoadjuvant therapy

Surgical technique and transplant procedure

Post-transplant follow-up

Living donor liver transplantation

Discussion and conclusion

Liver transplant for intrahepatic cholangiocarcinoma

Lack of data on selection criteria and neoadjuvant therapy

Expanding the role of liver transplantation in iCCA treatment

Liver transplant criteria launched at Houston Methodist-MD Anderson Cancer Center

Retrospective data analysis on transplant patients with iCCA

Liver transplantation for cholangiocarcinoma: From perihilar to intrahepatic

5 - Transplantation for metastatic colorectal cancer to liver

Evolution of LT for nCRLM

Patient, donor, and graft selection

Donor and graft selection

Recipient outcomes

Future directions and conclusion

Conflicts of interest

Author contributions

6 - Liver transplantation for neuroendocrine neoplasms liver metastases

Primary neuro-endocrine tumor

Metastatic liver disease

NELM diagnosis

NELM morphological pattern

NELM treatment

Liver transplantation for neuroendocrine liver metastases

Rationale

Results of liver transplantation for NELM

Comparison between liver transplantation and other treatment modalities

Specificities of liver transplantation for neuroendocrine liver metastases

Recipient selection

Milan criteria for LT for NELM

European Neuroendocrine Tumor Society criteria (ENETS guidelines)

UNOS guidelines (United Network for Organ Sharing).

Pre-transplantation work-up

Liver grafts and LT techniques

Immunosuppression and rejection

NENs metastases recurrence post liver transplantation

Prognostic factors for oncological long-term outcomes

Experience with LT for NELM at Cliniques Universitaires Saint Luc

Conclusions and future directions

7 - Hepatoblastoma

Hepatoblastoma (diagnosis, stratification and treatment)

Diagnosis

Stratification

Treatment

Liver transplantation in hepatoblastoma

Pre-operative

Intra-operative

Post-operative

Long-term outcomes

III - Transplant oncology and immunotherapy

8 - Transplant oncology and immunotherapy: Immunotherapy and liver transplants

ICPI pre-liver transplant: HCC bridging therapy

ICPI post-liver transplant: HCC palliative therapy

Assessment of immune checkpoint inhibitors

Does immunosuppression affect the efficacy of ICPIs?

Which ICPI class is safer?

Can liver biopsy help with patient selection and prediction of rejection?

Biomarkers for graft rejection

Bone marrow mesenchymal stem cells on acute rejection of liver allografts in rats

Liver enzymes

Cytokines and other markers related to inflammation

The timing of ICPI peri-transplant

What about adverse events of ICPIs?

Conclusions

9 - B. Immunotherapy and kidney transplant

Introduction-Immune check point inhibitors (ICI) use in solid organ transplant recipients

ICI use in solid organ transplant recipients

Mechanism of T-cell activation and regulation-Role in ICI therapy and solid organ transplantation

Immune check point inhibitor use in solid organ transplants

Current usage of ICI in cancers

Previous experience

Mechanism of SOT rejection after ICI

Loss of T-cell regulation

Histopathological studies.

Immune suppression role to prevent SOT rejection

Effect of immunosuppression on tumor progression and survival

Tumor response versus graft survival

Belatacept

Early markers of rejection

Gene expression studies

10 - Immunotherapy and hematopoietic stem cell transplantation

Background

Historical background from the beginnings of hematopoietic stem cell transplantation

Types of hematopoietic stem cell transplantation

Autologous stem cell transplantation

Allogeneic stem cell transplantation

Patient and donor selection for transplant

Patient and disease assessments

Donor assessment

Graft source and stem cell dose

Donor HLA compatibility and donor choice

Donor health assessment

Conditioning regimen

Myeloablative conditioning (MAC)

TBI-based regimens

High-dose chemotherapy-based regimens

Non-myeloablative (NMA) and reduced-intensity conditioning (RIC)

GVHD prophylaxis

Matched sibling donor (MSD)

Matched unrelated donor (MUD)

Haploidentical donor

Posttransplant complications

Graft failure

GVHD

Infections

VOD/SOS

Late complications

11 - Immunotherapy in the era of transplant oncology: Risks and complications

Current landscape of immunotherapy

CTLA-4 inhibitors

PD-L1 and PD-1 inhibitors

LAG-3 inhibitors

Use of immunotherapy in solid organ transplant recipients

Molecular features of solid organ transplant rejection

Safety of immunotherapy use in solid organ transplant recipients

Tumor responses to immunotherapy in SOTRs

Prevention and management of immunotherapy-induced solid organ transplant rejection

Future directions

12 - Immunotherapy and immunosuppressants: Considerations in the clinical practice.

Introduction: Epidemiology of cancers post-kidney transplant

Immunosuppression management in patients with cancer

Use of immune checkpoint blockade in kidney transplant

Risk of rejection

Management of immunosuppression for patients receiving ICI

Shared decision making in use of ICI

CAR-T therapies immunosuppression management and rejection risk

IV - Transplant oncology and precision medicine

13 - Molecular profiling and next-generation sequencing applications in transplant oncology

How to implement molecular profiling into liver transplant care

Potential roles of molecular profiling by stage of liver transplant care

At referral and evaluation for germline cancer predisposition

At referral and evaluation for cancer screening and diagnosis

At waitlist and liver transplant, for prognosis

At waitlist and liver transplant, for predicting therapeutic responses

Follow up, for minimal residual disease and cancer surveillance

Implementation barriers

Patient recruitment/compliance

Specimen acquisition/transport

Testing cost/scale/turnaround time

Multidisciplinary molecular tumor board

Actionability: Follow-up tests, targeted therapies, trial access

Summary

Financial support

14 - Circulating tumor DNA (ctDNA) as a new and evolving tool in solid organ transplantation

Liquid biopsy-An introduction

ctDNA platforms

Screening or early detection

Minimal residual disease (MRD) detection

Genotyping for actionable markers

The road ahead

15 - Cell-free DNA (cfDNA) biomarkers for solid organ transplant rejection

Characterization of cell-free DNA

Concentration

Epigenetic modifications

Fragment size

Clearance kinetics

Assays.

Kinetics of donor-derived cell-free DNA (dd-cfDNA) levels in recipients with stable grafts.

Notes:

Includes bibliographical references and index.

Description based on publisher supplied metadata and other sources.

Description based on print version record.

ISBN:

9780443219023

0443219028

OCLC:

1470859867